Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statement of Changes in Stockholders' Equity (Unaudited)

v3.10.0.1
Consolidated Statement of Changes in Stockholders' Equity (Unaudited) - 9 months ended Sep. 30, 2018 - USD ($)
Common Stock [Member]
Preferred Stock [Member]
Additional Paid-In Capital [Member]
Subscription Receivable [Member]
Accumulated Deficit [Member]
Total
Balance at Dec. 31, 2017 $ 3,527 $ 4,228,723 $ (3,859,087) $ 373,163
Balance, shares at Dec. 31, 2017 35,272,626        
Recognize the fair value of exclusive license intangible asset acquired from CoNCERT in exchange for 2,090,301 common shares of Processa owned by Promet 8,000,000 8,000,000
Conversion of Senior convertible notes for common stock and stock purchase warrants, net of costs of $4,742 $ 121 $ 2,390,248 $ 2,390,369
Conversion of Senior convertible notes for common stock and stock purchase warrants, net of costs of $4,742, shares 1,206,245        
Issuance of common stock units for cash, net of costs of $218,422 $ 140 2,964,955 2,965,095
Issuance of common stock units for cash, net of costs of $218,422, shares 1,402,442        
Issuance of common stock units for a clinical trial funding commitment, net of costs of $117,339 $ 79 1,682,582 (1,800,000) (117,339)
Issuance of common stock units for a clinical trial funding commitment, net of costs of $117,339, shares 792,952        
Stock-based compensation 50,528 50,528
Net loss for the nine months ended September 30, 2018 (3,155,874) (3,155,874)
Balance at Sep. 30, 2018 $ 3,867 $ 19,317,036 $ (1,800,000) $ (7,014,961) $ 10,505,942
Balance, shares at Sep. 30, 2018 38,674,265